I don't know if you're being sarcastic bedger, but there is no more information in this presentation than they have previously released.
Still no idea how many patients were cured vs improved, as an absolute minimum.
The primary endpoint of the trial was the "evaluation of the systemic bioavailability". There has been no explanation or outcome reported of the PRIMARY ENDPOINT of the trial, except to say that it was "met". How this is even remotely defensible by anyone is a complete mystery to me.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.005(1.67%) |
Mkt cap ! $85.06M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 29.5¢ | 29.0¢ | $38.76K | 133.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 135000 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 9819 | 2 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |